Beijing Biostar Pharmaceuticals Co Ltd (hkse:02563) Share Price

Company Profile

Business description
Beijing Biostar Pharmaceuticals Co Ltd is a synthetic biology-driven biopharmaceutical company committed to developing innovative drugs in oncology. It has developed three core technology platforms that focus on the R&D of microbial metabolite new drugs. Its Core Product and 16 out of 19 product candidates are based on a single active pharmaceutical ingredient, namely, Utidelone, which was represented in three formulations of its product portfolio. The company's current clinical trials and programs of the Core Product and product candidates cover indications of advanced breast cancer, advanced non-small cell lung cancer, neoadjuvant for breast cancer, gastric cancer, esophageal cancer, breast cancer brain metastasis, lung cancer brain metastasis, glioblastoma, and other solid tumors.
Contact
22 Ronghua Middle Road
Suite 1202, Tower B, Yicheng Fortune Center
Beijing Economic-Technological Development Area
Beijing100176
CHN
T: +86 1067864938
https://www.biostar-pharm.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees

Recommended

Investors may be over optimistic about the prospects for a new revenue source.

Roy van Keulen | 02 March 2025

The longer term outlook for these moated companies looks far brighter than markets seem to be giving them credit for.

Joseph Taylor | 02 March 2025

Are the shares of two of Australia’s best known brands attractive?

Johannes Faul | 27 February 2025

Index	Last price	Change	% Change
All Ordinaries	8,403.90	102.20	-1.20%
CAC 40	8,111.63	9.11	0.11%
DAX 40	22,551.43	0.54	0.00%
Dow JONES (US)	43,840.91	601.41	1.39%
FTSE 100	8,809.74	53.53	0.61%
HKSE	22,941.32	776.97	-3.28%
NASDAQ	18,847.28	302.86	1.63%
Nikkei 225	37,155.50	1,100.67	-2.88%
NZX 50 Index	12,517.78	83.64	-0.66%
S&P 500	5,954.50	92.93	1.59%
S&P/ASX 200	8,172.40	95.80	-1.16%
SSE Composite Index	3,320.90	67.17	-1.98%